Illumina, Inc.

Agendia Partners with Illumina to Expand Genomic Testing in Breast Cancer Care

Retrieved on: 
Monday, January 10, 2022
Research, Genetics, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Oncology, Marie Cassidy, Patient, Corporate development, Surgeon, IVD, Biology, NGS, Partnership, Breast cancer, NASDAQ, Oncology, Illumina, Inc., Health, Recurrence, CPT, Prognosis, Diagnosis, Behavior, FDA, Physician, Woman, Medical imaging, Pharmaceutical industry, MammaPrint, Illumina

Agendia joins Illuminas growing portfolio of more than 30 IVD partners developing over 40 sequencing-based solutions for cancer prognosis, therapy selection, and other applications.

Key Points: 
  • Agendia joins Illuminas growing portfolio of more than 30 IVD partners developing over 40 sequencing-based solutions for cancer prognosis, therapy selection, and other applications.
  • Illumina and Agendia plan to develop new tests to enhance the care and management of breast cancer patients, utilizing the Illumina MiSeqDx sequencing platform to expand the range of gene panels available for solid tumor analysis.
  • Together, we plan to expand what is possible in breast cancer care and ensure that the essential insights that come from genomic testing are delivered to patients around the world.
  • We are pleased to partner with Agendia, with its deep expertise in genomic testing in breast cancer, to expand the reach of NGS-based genomic testing in cancer care, said Joydeep Goswami, Chief Strategy and Corporate Development Officer of Illumina.

Knight Cancer Institute at Oregon Health & Science University to Offer the Galleri® Multi-Cancer Early Detection Test

Retrieved on: 
Monday, January 10, 2022
Biotechnology, Health, Consumer, Pharmaceutical, Oncology, University, Research, Medical Devices, Managed Care, Education, Hospitals, Science, Seniors, Cardiology, Prostate-specific antigen, Trial of the century, Risk, Colon, American Joint Committee on Cancer, Ageing, Clinical Laboratory, Illumina, Inc., American Cancer Society, Oregon Health & Science University, Cancer, Patient, United Kingdom, NASDAQ, CLIA, Lung, Knight Cancer Institute, OHSU, Colonoscopy, Food, Diagnosis, Prostate, Technology, Cervical cancer, College of American Pathologists, List of pathologists, Breast, PSA, Mammography, LLC, College, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Mortality, Pharmaceutical industry, Medical imaging, Medical device, The McLoughlin Gallery, GRAIL, Galleri, GRAIL, GALLERI, GRAIL

GRAIL, LLC, a healthcare company whose mission is to detect cancer early, today announced a collaboration with the Knight Cancer Institute at Oregon Health & Science University (OHSU) to offer Galleri, GRAILs multi-cancer early detection (MCED) blood test.

Key Points: 
  • GRAIL, LLC, a healthcare company whose mission is to detect cancer early, today announced a collaboration with the Knight Cancer Institute at Oregon Health & Science University (OHSU) to offer Galleri, GRAILs multi-cancer early detection (MCED) blood test.
  • Beginning this month, the Galleri test will be offered to eligible patients through the OHSU Knight Cancer Institute.
  • Multi-cancer early detection is a true game-changing technology in how we detect and treat cancer, said Tom Beer, M.D., deputy director of the OHSU Knight Cancer Institute and chief medical officer of the Knight Cancer Institutes Cancer Early Detection Advanced Research (CEDAR) Program.
  • After evaluating how the Galleri test worked in the clinical trial setting, we are now able to offer eligible patients access to the test.

GRAIL and Premier’s PINC AI™ Partner to Support Patient Access to Galleri® Multi-Cancer Early Detection Blood Test

Retrieved on: 
Monday, January 10, 2022
Medical Devices, Seniors, Hospitals, Cardiology, Biotechnology, Managed Care, Pharmaceutical, Consumer, Health, Oncology, Intelligence, Prostate-specific antigen, Risk, Contigo, Colon, Disease, American Joint Committee on Cancer, Ageing, LinkedIn, Clinical Laboratory, Illumina, Inc., Community health, American Cancer Society, Cancer, Patient, Premier, Inc., United Kingdom, NASDAQ, CLIA, Lung, NYSDOH, CLEP, Partnership, Guideline, Colonoscopy, Food, Workflow, Diagnosis, Prostate, Abrazo Community Health Network, Organization, New York State Department of Health, Technology, Cervical cancer, College of American Pathologists, List of pathologists, Breast, PSA, Twitter, Mammography, LLC, College, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry, Medical device, Medical imaging, The McLoughlin Gallery, GRAIL, Galleri, GRAIL, PINC AI, GALLERI, GRAIL, PINC AI

Under the partnership, Premiers PINC AI will augment its AI-enabled clinical decision support technology to alert clinicians to patients who present an elevated risk of cancer and may benefit from early detection with the Galleri test.

Key Points: 
  • Under the partnership, Premiers PINC AI will augment its AI-enabled clinical decision support technology to alert clinicians to patients who present an elevated risk of cancer and may benefit from early detection with the Galleri test.
  • The partnership with Premiers PINC AI, a trusted leader in healthcare technology, will support a key pillar of new early cancer detection technology the identification of eligible patients through healthcare providers existing workflows.
  • PINC AI augments clinical intelligence and helps ensure patients receive evidence-based care, said Leigh Anderson, president of Premiers PINC AI.
  • With this collaboration between PINC AI and GRAIL, our clinicians will be alerted when patients meet certain criteria for the ordering of a Galleri test.

Global Long Read Sequencing Market Research Report (2021 to 2026) - by Technology, Product, Workflow, Application, End-user and Region

Retrieved on: 
Thursday, January 6, 2022
Investment, Customer support, Honeywell, COVID-19, Business Growth Fund, JPY, Acquisition, CAGR, Market share analysis, Growth, PerkinElmer, EUR, AUD, Intel, Long, USD, Decision-making, LLC, Use, Strategic management, Genomics, Certification, Illumina, Inc., Value, R, Thermo Fisher Scientific, Retail, Fine chemical, Camera

What are the inhibiting factors and impact of COVID-19 shaping the Global Long Read Sequencing Market during the forecast period?

Key Points: 
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Long Read Sequencing Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Long Read Sequencing Market?
  • What is the market share of the leading vendors in the Global Long Read Sequencing Market?
  • What modes and strategic moves are considered suitable for entering the Global Long Read Sequencing Market?

Global Transplant Diagnostics Market Research Report 2021 Featuring Thermo Fisher Scientific, Illumina, F. Hoffmann La-Roche AG., Abbott Laboratories, and Qiagen N.V. - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 6, 2022
Surgery, Health, Medical Devices, COVID-19, Organ transplantation, Food, GLP, Distortion, Health Resources and Services Administration, US Foods, Growth, DNA, MLC, Transplant, NGS, Good laboratory practice, NSG, Health, Abbott Laboratories, Gene, FDA, HLA, Next Generation, Genome, Method, Somatic mutation, Illumina, Inc., Technology, HRSA, Maintenance, DNA sequencing, Medical device, Dentistry

The "Transplant Diagnostics Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Transplant Diagnostics Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Major players in the transplant diagnostics market are Thermo Fisher Scientific, Inc., Illumina, Inc., F. Hoffmann La-Roche AG., Abbott Laboratories, Inc. and Qiagen N.V.
  • The transplant diagnostics market consists of sales of transplant diagnostics test products and related services.
  • Huge gap between organ donation and demand for organ transplantation is restraining the growth of the transplant diagnostics market.

New Study from StrategyR Highlights a $1.2 Billion Global Market for Next Generation Sequencing (NGS) Data Analysis by 2026

Retrieved on: 
Tuesday, January 4, 2022
Cloud, COVID-19, CAGR, Eurofins Scientific, Growth, Forecasting, Sophia Genetics, Algorithm, Awareness, GIA, Diagnosis, Technology, DNA sequencing, Clinical research, Clifton Springs Hospital & Clinic, Intelligence, Research, Software, Pacific Biosciences, Wellcome Sanger Institute, Breast, NGS, Data lake, Service, Agilent Technologies, Method, Thermo Fisher Scientific, Marketing, Automation, RNA, Hospital, SAN, Globe, Cloud computing, Data analysis, Internet, Players, Geography, DNA, Prevalence, Adoption, Illumina, Inc., Solution, Pharmaceutical industry, Illumina, Qiagen, Others, Workflow

SAN FRANCISCO, Jan. 4, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Next Generation Sequencing (NGS) Data Analysis - Global Market Trajectory & Analytics" .

Key Points: 
  • SAN FRANCISCO, Jan. 4, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Next Generation Sequencing (NGS) Data Analysis - Global Market Trajectory & Analytics" .
  • NGS data analysis encompasses primary, secondary and tertiary analysis steps, with some of these stages holding potential for automation through new sequencing solutions.
  • This segment currently accounts for a 44% share of the global Next Generation Sequencing (NGS) Data Analysis market.
  • Companies lacking the necessary infrastructure for data analysis, interpretation, and management are increasingly adopting cost-effective NGS data analysis services.

Illumina and Syapse Partner on Research to Evaluate Large Panel Biomarker Testing Patterns Across US Community Oncology Practices

Retrieved on: 
Tuesday, January 4, 2022
Research, Patient, Clinical trial, SAN, Hope, GLOBE, Decision-making, NASDAQ, Cancer, Precision medicine, Illumina, Inc., Biomarker, Fear, Partnership, Quality of life, Â, Medical imaging, Illumina

(NASDAQ:ILMN),aimed at assessing the real-world uptake and actionability of comprehensive genomic profiling in the community oncology health system setting.

Key Points: 
  • (NASDAQ:ILMN),aimed at assessing the real-world uptake and actionability of comprehensive genomic profiling in the community oncology health system setting.
  • As such, the work between Syapse and Illumina seeks to understand biomarker testing patterns and actionability of test results to inform clinical decision-making in the community health system setting as a first step toward facilitating improved clinical decision making.
  • We are very proud to be working with Illumina to generate trusted insights surrounding biomarker testing patterns that we hope can be used to advance real-world care and bring a higher standard of care to all oncology patients.
  • Syapse is a company dedicated to extinguishing the fear and burden of serious disease by advancing real-world care.

Global Cancer Microbiome Sequencing Market (2021 to 2031) - Featuring CD Genomics, GoodGut and Qiagen Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 4, 2022
Health, Oncology, Research report, Biotechnology, COVID-19, Technology, Adoption, Awareness, Biomarker, Research, CAGR, Investment, Physician, Illumina, Inc., Cancer, Industry, Dietary supplement, Antibiotics

Currently, the cancer microbiome sequencing industry is witnessing an upsurge due to the increasing emphasis on the microbiome's potential in the field of cancer, global increase in cancer prevalence, and decreasing cost of sequencing.

Key Points: 
  • Currently, the cancer microbiome sequencing industry is witnessing an upsurge due to the increasing emphasis on the microbiome's potential in the field of cancer, global increase in cancer prevalence, and decreasing cost of sequencing.
  • The development of cancer microbiome sequencing products and services enabled the research community to establish effective strategies for discovering novel cancer biomarkers associated with the microbiome, which could be harnessed for the development of cancer microbiome sequencing products for clinical use.
  • What are the major market drivers, challenges, and opportunities in the global cancer microbiome sequencing market?
  • What are the underlying structures resulting in the emerging trends within the global cancer microbiome sequencing market?

Worldwide Biochips Industry to 2026 - Featuring Agilent Technologies, bioMerieux and Dynamic Biosensors Among Others

Retrieved on: 
Tuesday, December 21, 2021
Drug discovery, Infection, Illumina, Inc., DNA, Antibody, Protein, Investment, Thermo Fisher Scientific, Laboratory, COVID-19, Biotechnology, Research, Prevalence, CAGR, Proteome, Biochip, Collection, Gene expression profiling, Degenerative disease, Industry, Enzyme, Agilent Technologies, Cancer, Nanotechnology, Animal, Fine chemical, Vaccine, Potash, Growth

Biochips refer to a miniaturized medical device that includes a wide collection of microarrays for performing multiple biochemical reactions simultaneously.

Key Points: 
  • Biochips refer to a miniaturized medical device that includes a wide collection of microarrays for performing multiple biochemical reactions simultaneously.
  • They contain numerous biosensors that enable the screening of several biological analytes such as enzymes, proteins, DNA, biological molecules, antibodies, etc.
  • Biochips are primarily used in drug discovery, in-vitro diagnostics, gene expression profiling, single nucleotide polymorphism genotyping, agricultural biotechnology, etc.
  • What is the structure of the global biochips market and who are the key players?

numares Appoints Dr. Gregory Heath As New Member of the Supervisory Board and Submits an Additional Test to the FDA

Retrieved on: 
Wednesday, December 15, 2021
Research, Medical Devices, Venture Capital, FDA, Professional Services, Biotechnology, Pharmaceutical, Health, Science, Other Science, Roche Diagnostics, LinkedIn, Solution, FDA, Coronavirus Scientific Advisory Board (Turkey), Algorithm, Supervisory board, Illumina, Inc., Christopher Numar of Forli, Industry, IVD, Kidney, Cancer, Acquisition, Urine, SVP, Lists of television programs, Liver, General manager, Marketing, Machine learning, NMR, Knowledge, Disease, Multimedia, YouTube, Twitter, Blood, CLIA, AG, Heart, Medical device, Facebook

Leading NMR diagnostics company numares AG appoints Dr. Gregory Heath as new member of the Supervisory Board.

Key Points: 
  • Leading NMR diagnostics company numares AG appoints Dr. Gregory Heath as new member of the Supervisory Board.
  • View the full release here: https://www.businesswire.com/news/home/20211215005040/en/
    Dr. Gregory F. Heath, Member of the numares Supervisory Board (Photo: Business Wire)
    We are delighted to welcome Greg to the board, said Dr. Volker Pfahlert, Chief Executive Officer of numares.
  • Winton Gibbons, President of numares GROUP in the US and co-CEO of numares AG adds "Greg is a great addition to our Supervisory Board.
  • At the numares shareholders meeting in December 2021, Dr. Heath was elected as member of the supervisory board effective January 1st, 2022.